IL6 and COVID-19: Tocilizumab, a recombinant humanized monoclonal antibody directed against the IL-6 receptor, has shown a mortality benefit in severe cases of COVID-19 [36,37], underscoring the potential of IL-6 as a therapeutic target in patients with cancer and COVID-19.